Sunitinib Combined with Angiotensin-2 Type-1 Receptor Antagonists Induces More Necrosis: A Murine Xenograft Model of Renal Cell Carcinoma

Figure 4

Sunitinib in combination with telmisartan significantly decreases central MVD and tends to decrease seric VEGF-A concentration. (a) Evaluation of central microvascular density by CD31 staining of tumors in a control tumor or after treatment with sunitinib alone, telmisartan alone, and combination (×100). (b) Quantification of central microvascular density as number of vessels per mm². (c) Quantification of seric VEGF-A concentration by ELISA method. Mean ± SEM, ^∗𝑃<0.05, ^∗∗𝑃<0.02, and ^∗∗∗𝑃<0.001.

(a)

(b)

(c)